Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Thermo Fisher Scientific Inc

285 views

Published on

  • ⇒ www.HelpWriting.net ⇐ This service will write as best as they can. So you do not need to waste the time on rewritings.
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

Thermo Fisher Scientific Inc

  1. 1. Mesfin Symons & Sean McGrath
  2. 2. Stock Summary • NYSE Ticker: TMO • Sector: Health Care • Industry: Life Sciences Tools & Services • Recommend: BUY  Market Cap: $52.0B  52 week low:$117.1  52 week high:$170.0  Target price:$165.46
  3. 3. OVERVIEW  Headquartered in Waltham, MA  50,000+ employees  50 countries  $17 Billion in annual revenue
  4. 4. What they do Provides  Analytical instruments  Equipment  Ect. Serves:  Biotechnology  Academic  Ect.
  5. 5. Executives  Marc N. Casper CEO  Alan B. Sachs CSO  Peter M. Wilver CFO
  6. 6. Business segment overview  Life Sciences Solutions  Analytical Instruments  Specialty diagnostics  Laboratory Products and Services
  7. 7. Strategy for growth
  8. 8. Financials
  9. 9. Financials Metric. TMO Industry Avg. Market Cap $52.17B $2.4B Beta 0.97 .98 EPS $4.92 $3.81 Operating Margin 14.78% -61.02% P/E 26.58 29.81 D/E 58.55% 38.62% Total Revenue $16.97B $7.09B Revenue Growth 0.45% 5.15% Shares Outstanding $399.10M 214.13B
  10. 10. Competitors NAME TICKER MARKET CAP EPS REVENUE Illumina ILMN $23.66B $3.1 $2.22B Waters Corp WAT $10.3B $5.65 $2.0B Becton, Dickinson and Co BDX $31.59 $3.25 $11.22B Agilent Technologies Inc. A $13.1B $1.40 $4.0B
  11. 11. Risks  Large debt  Unstable economies  Lawsuits  Currency exchange rates  Healthcare reform legislation
  12. 12. Growth  Innovation across segments  Presence in Emerging Market  Long-term Shareholder Value
  13. 13. Growth
  14. 14. Summary  Largest player in field  Constant revenue growth  Multi-faceted strategy for growth  Emerging markets  Innovation
  15. 15. DCF  Historical
  16. 16. DCF  Base case
  17. 17. DCF  Downside
  18. 18. DCF  Output
  19. 19. Q&A
  20. 20. Q&A
  21. 21. Q&A
  22. 22. Analyst Price Target Summary  Mean Target: $150.5  Median Target: $151.00  High Target: $170.00
  23. 23. Q&A  Hedging: “The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Swiss franc, Japanese yen, Norwegian kroner, and Swedish kronor.”  Share Buybacks  “The company expects its effective tax rate in 2016 will be less than 3% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits.”
  24. 24. Competitors VS Segments Revenue (Billions) R&D Illumina $2.224 10% Agilent Technologies $4.0 8% Becton, Dickson, and CO $11.22 5.6% Water Corp inc $2.0 1.2% Revenue (Billions) R&D Life Sciences Solutions $4.44 7.4% Analytical Instruments $3.21 6.3% Specialty Diagnostics $3.29 5.2% Laboratory Products and Services $6.6 2.54%

×